Vaxcell-Bio Therapeutics KRX:323990KOSDAQ

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

1. 1
   Parcelbio unveils solid tumor treatment research at international conference…Upside

   3 outlets · 3 articlesFirst report Nov 9 10:21 조선비즈
2. 2
   Parksel Bio unveils next-generation CAR therapy results at SITC 2026

   2 outlets · 2 articlesFirst report Nov 9 09:37 뉴스타운
3. 3
   Tomorrow's market outlook: 'Park Cellbio KTCS Daemyung Energy' expected to be big winners?

   2 outlets · 2 articlesFirst report Nov 10 06:08 MTNDae Myoung Energy
4. 4
   Parcel Bio shows 11 of 16 hepatocellular carcinoma patients responded…Knocking on door for 'First-in-Korea Act 2'

   1 outlets · 2 articlesFirst report Nov 2 08:16 이데일리
5. 5
   Parcelbio CAR-T achieves complete remission in solid tumors—Alteogen and CJ Gene down

   1 outlets · 2 articlesFirst report Nov 11 07:11 이데일리SeegeneAlteogen
6. 6
   Boxcel Bio presents CAR therapy preclinical results for solid tumors and multiple myeloma at SITC

   1 outlets · 1 articlesFirst report Nov 9 11:10 글로벌경제신문Clinical trial

• Nov 1107:12
  Parcelbio CAR-T achieves complete remission in solid tumors—Alteogen and CJ Gene down

  이데일리SeegeneAlteogen

  1 more on this story · 1 outlets

  • Parcelbio CAR-T achieves complete remission in solid tumors—Alteogen and CJ Gene down이데일리 · Nov 11 07:11
• Nov 1006:08
  Tomorrow's market outlook: 'Park Cellbio KTCS Daemyung Energy' expected to be big winners?

  MTNDae Myoung Energy

  1 more on this story · 1 outlets

  • Tomorrow's market outlook: 'Park Cellbio KTCS Daemyung Energy' expected to be big winners?머니투데이 · Nov 10 06:19
• Nov 917:40
  Poxel Bio conducts preclinical trials for new anticancer drug, confirms prolonged efficacy in solid tumors

  이뉴스투데이
• Nov 915:42
  Stock Price: Key pharmaceutical, biotech, device 5% swings on November 9 - Baxcelbiopharm at limit-up

  메디파나뉴스
• Nov 913:35
  Parcel Bio hits limit-up on dual-target CAR-T showing complete remission in liver cancer model

  한국경제
• Nov 913:18
  MajorFeaturedParcel Bio hits limit-up on 100% complete remission rate in preclinical solid tumor CAR-T

  남도일보Clinical trial
• Nov 912:30
  Parcelbio unveils next-generation cell therapy research at US SITC

  PRESS9
• Nov 911:10
  MajorBoxcel Bio presents CAR therapy preclinical results for solid tumors and multiple myeloma at SITC

  글로벌경제신문Clinical trial
• Nov 910:21
  FeaturedParcelbio unveils solid tumor treatment research at international conference…Upside

  조선비즈

  2 more on this story · 2 outlets

  • Parcelbio unveils solid tumor treatment research at international conference…Upside조선일보 · Nov 9 10:24
  • Paselbio announces solid tumor treatment research results, stock up 25.8%뉴스드림 · Nov 9 11:58
• Nov 909:50
  Boxel Bio's dual-target CAR-T shows complete response in solid tumor preclinical study

  한국경제
• Nov 909:43
  Parcelbio confirms CAR-T complete remission at 100%…Accelerates clinical development

  한스경제
• Nov 909:37
  Parksel Bio unveils next-generation CAR therapy results at SITC 2026

  뉴스타운

  1 more on this story · 1 outlets

  • Parcelbio presents next-generation CAR therapy candidate results at American Immunotherapy Society더바이오 · Nov 9 09:42
• Nov 909:18
  Parksel Bio presents two CAR therapy research outcomes at SITC 2026

  데일리한국
• Nov 408:02
  Parkway Bio eyes revised biotech law...chaperones and HLB also drawing attention

  이데일리HLBShaperon
• Nov 208:17
  Parcel Bio shows 11 of 16 hepatocellular carcinoma patients responded…Knocking on door for 'First-in-Korea Act 2'

  이데일리

  1 more on this story · 1 outlets

  • Parcel Bio shows 11 of 16 hepatocellular carcinoma patients responded…Knocking on door for 'First-in-Korea Act 2'이데일리 · Nov 2 08:16
• Oct 3012:10
  Major"Dream cancer drug CAR-T surpassed"...BoxelBio to apply for IND next year

  아이뉴스24Clinical trial
• Oct 2811:03
  MajorParcel Bio: CAR-MIL shows 100% survival rate in animal testing, comparable to J&J Cabiktivi

  이데일리Clinical trial

  1 more on this story · 1 outlets

  • Parcel Bio: CAR-MIL shows 100% survival rate in animal testing, comparable to J&J Cabiktivi이데일리 · Oct 28 11:01
• Oct 1914:28
  Curien and Parcelbio present cancer drug research results at ESMO

  히트뉴스Qurient
• Oct 1911:05
  Paselbio reveals CAR-MIL multiple myeloma therapeutic research results at ESMO

  뉴스타운

  4 more on this story · 3 outlets

  • Paselbio unveils CAR-MIL multiple myeloma therapeutic at ESMO핀포인트뉴스 · Oct 19 11:09
  • Paselbio presents CAR-MIL multiple myeloma therapeutic research poster at ESMO이데일리 · Oct 19 11:29
  • Paselbio presents CAR-MIL multiple myeloma therapeutic research poster at ESMO이데일리 · Oct 19 11:30
  • Paselbio reveals CAR-MIL multiple myeloma therapeutic research results at ESMO and others including DT&CRO and Microdigital글로벌경제신문 · Oct 19 14:13
• Oct 1910:31
  Boxel Bio announces multiple myeloma treatment preclinical data at ESMO

  뉴시스경제
• Oct 1910:30
  Boxel Bio's multiple myeloma drug candidate takes ESMO stage

  한스경제
• Oct 1623:10
  Boxel Bio VCB-1102 hepatocellular carcinoma phase 2a paper released

  메디포뉴스
• Oct 1615:24
  Boxel Bio announces phase 2a results for autologous NK cell therapy VCB-1102, Ligachem Bio, Apta Biotech

  글로벌경제신문LigaChem BiosciencesAptabio Therapeutics
• Oct 1614:46
  Boxel Bio publishes paper on VCB-1102 with 68.75% hepatocellular carcinoma response rate…but question mark on additional NK effects

  뉴데일리경제Clinical trialNK
• Oct 1610:07
  Boxel Bio's NK cell therapy VCB-1102 phase 2a clinical results published in international journal

  이데일리

  2 more on this story · 2 outlets

  • Boxel Bio's NK cell therapy VCB-1102 phase 2a clinical results published in international journal이데일리 · Oct 16 10:05
  • Boxel Bio hepatocellular carcinoma NK cell therapy phase 2a clinical paper published in international journal한국금융신문 · Oct 16 10:15
• Oct 1610:06
  MajorBoxel Bio announces NK cell therapy phase 2a published in international journal

  뉴시스경제New technology
• Oct 1610:00
  MajorBoxel Bio's autologous NK cell therapy VCB-1102 phase 2a clinical data published in international journal

  더바이오New technology
• Oct 1609:59
  MajorBoxel Bio VCB-1102 phase 2a hepatocellular carcinoma published in international journal…response rate 68.75%

  PRESS9Clinical trial

  1 more on this story · 1 outlets

  • Boxel Bio's VCB-1102 shows 68.75% response rate in phase 2a hepatocellular carcinoma trial…published in international journal한국경제 · Oct 16 10:24
• Sep 2910:27
  Boxel Bio targets both human and animal cancer treatment markets…expanding immune cell therapy research

  이뉴스투데이
• Sep 2908:16
  Boxel Bio: why submit clinical research despite VCB-1102 risk adjustment

  이데일리

  1 more on this story · 1 outlets

  • Boxel Bio: why submit clinical research despite VCB-1102 risk adjustment이데일리 · Sep 29 08:16